Table 5.
VTE | No VTE | P value | |||
---|---|---|---|---|---|
Mean (SD) | Median | Mean (SD) | Median | ||
Utilization | |||||
Inpatient admissions (n) | 2.2 (1.7) | 2 | 0.6 (1.0) | 0 | <0.0001a |
Length of stay (d) | 55.1 (62.7) | 31 | 8.7 (24.7) | 0 | <0.0001a |
Outpatient visits (n) | 28.1 (23.4) | 23 | 11.2 (12.9) | 7 | <0.0001a |
Pharmaceutical claims (n) | 13.3 (14.0) | 9 | 4.7 (7.3) | 2 | <0.0001a |
Expendituresb | |||||
Inpatient admissions | $316 379 (465 967) | $113 386 | $29 678 (118 303) | $0 | <0.0001a |
Outpatient visits | $25 866 (43 160) | $13 570 | $6 838 (18 085) | $2556 | <0.0001a |
Pharmaceutical claims | $2561 (6835) | $486 | $585 (3322) | $36 | <0.0001a |
Total expenditures | $344 807 (471 323) | $152 339 | $37 102 (123 180) | $4517 | <0.0001 |
Total expenditures (adjusted)b | $93 780 (235 613) | $51 543 | $42 725 (107 343) | $23 483 | <0.0001 |
CPHD, chronic pediatric heart disease; SD, standard deviation; VTE, venous thromboembolism.
Wilcoxon rank‐sum test.
Estimate adjusted for age, noncardiac complex chronic conditions, recent trauma, recent infection, recent cardiac surgery, recent noncardiac surgery, and acquired acute cardiovascular conditions.